Schizophrenia, a devastating psychiatric disorder, has a prevalence of 0.5–1%, with high heritability (80–85%) and complex transmission1. Recent studies implicate rare, large, high-penetrance copy number variants in some cases2, but the genes or biological mechanisms that underlie susceptibility are not known. Here we show that schizophrenia is significantly associated with single nucleotide polymorphisms (SNPs) in the extended major histocompatibility complex region on chromosome 6. We carried out a genome-wide association study of common SNPs in the Molecular Genetics of Schizophrenia (MGS) case-control sample, and then a meta-analysis of data from the MGS, International Schizophrenia Consortium and SGENE data sets. No MGS finding achieved genome-wide statistical significance. In the meta-analysis of European-ancestry subjects (8,008 cases, 19,077 controls), significant association with schizophrenia was observed in a region of linkage disequilibrium on chromosome 6p22.1 (P = 9.54 × 10-9). This region includes a histone gene cluster and several immunity-related genes—possibly implicating aetiological mechanisms involving chromatin modification, transcriptional regulation, autoimmunity and/or infection. These results demonstrate that common schizophrenia susceptibility alleles can be detected. The characterization of these signals will suggest important directions for research on susceptibility mechanisms.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data have been deposited at dbGaP (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap) under accessions phs000021.v2.p1 and phs000167.v1.p1, and the NIMH Center for Collaborative Genetic Studies on Mental Disorders (http://www.nimhgenetics.org) under studies 6, 29 and 29C.
We thank the study participants, and the research staff at the study sites. This study was supported by funding from the National Institute of Mental Health (USA) and the National Alliance for Research on Schizophrenia and Depression. Genotyping of part of the sample was supported by the Genetic Association Information Network (GAIN), and by The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Center for Genotyping and Analysis at the Broad Institute of Harvard and MIT with support from the National Center for Research Resources (USA). The GAIN quality control team (G. R. Abecasis and J. Paschall) made important contributions to the project. We thank S. Purcell for assistance with PLINK.
Author Contributions J.S., D.F.L. and P.V.G. wrote the first draft of the paper. P.V.G., D.F.L., A.R.S., B.J.M., A.O., F.A., C.R.C., J.M.S., N.G.B., W.F.B., D.W.B., R.R.C. and R.F. oversaw the recruitment and clinical assessment of MGS participants, and the clinical aspects of the project and analysis. A.R.S., D.F.L. and P.V.G. performed database curation. D.F.L., J.S., I.P., F.D., P.A.H., A.S.W. and P.V.G. designed the analytical strategy and analysed the data. D.B.M. oversaw the Affymetrix 6.0 genotyping, and J.D., Y.Z., A.R.S. and P.V.G. performed the preparative genotyping and experimental work. J.R.O. contributed to the interpretation of data in the MHC/HLA region, and K.S.K. contributed to the approach to clinical data. P.V.G. coordinated the overall study. All authors contributed to the current version of the paper.
About this article
Translational bioinformatics in mental health: open access data sources and computational biomarker discovery
Briefings in Bioinformatics (2019)